Journals / The Anatolian Journal of Cardiology / 2016 / Cilt: 16 - Sayı: 6

Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey

Pages
370–384
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The low treatment and control levels among individuals based on their CHD risk levels call for a better application of recommendations regarding personal preventive measures and treatments in Turkey.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: High blood cholesterol is one of the main modifiable risk factors for cardiovascular diseases (CVDs).
📊
Key Findings & Data:The aim of the study is to determine the factors associated with the prevalence, awareness, treatment, and control of high "low-density lipoprotein-cholesterol" (LDL-C) among adults aged >=20 years in Turkey.Methods: We used data from Chronic Diseases and Risk Factors Survey conducted in 2011-2012.
💡
Conclusion & Impact:The low treatment and control levels among individuals based on their CHD risk levels call for a better application of recommendations regarding personal preventive measures and treatments in Turkey.
🔬Design:Survey & Empirical Study
📍Scope:2011-2012 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: High blood cholesterol is one of the main modifiable risk factors for cardiovascular diseases (CVDs). The aim of the study is to determine the factors associated with the prevalence, awareness, treatment, and control of high "low-density lipoprotein-cholesterol" (LDL-C) among adults aged >=20 years in Turkey.Methods: We used data from Chronic Diseases and Risk Factors Survey conducted in 2011-2012. The presence of high LDL-C, lipid-lowering treatment eligibility, and achievement of target LDL-C were defined according to the third Adult Treatment Panel guidelines on treatment of high cholesterol. Multivariate logistic regression analyses were performed to determine the associations between participant characteristics and high LDL-C prevalence, awareness, treatment, and control.Results: Framingham risk score categorization was performed for 13121 individuals aged >=20 years. Approximately, 28% of the participants presented with high LDL-C. Among those with high LDL-C, 55.8% were aware of their situation; among those aware of high LDL-C, 46.9% were receiving lipidlowering medication, and 50.6% of individuals who were receiving treatment achieved target LDL-C levels on the basis of their coronary heart disease (CHD) risk. Control of high LDL-C was negatively associated with the presence of diabetes mellitus (odds ratio: 0.36, 95% CI: 0.27-0.49, p<0.001).Conclusion: Despite the high awareness rates, there was a high proportion of adults who did not receive treatment or achieve recommended levels of LDL-C during treatment. The low treatment and control levels among individuals based on their CHD risk levels call for a better application of recommendations regarding personal preventive measures and treatments in Turkey.

🔖

Cite This Article

SÖZMEN, K., ÜNAL, B., SAKARYA, S., HORASAN, G. D., YARDIM, N., KESKİNKILIÇ, B., ERGÖR, G. (2016). Determinants of prevalence, awareness, treatment and control of high LDL-C in Turkey. The Anatolian Journal of Cardiology, Cilt: 16 - Sayı: 6, 370–384. https://ajindex.com/articles/366745

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. WHO. Global Atlas on Cardiovascular Disease Prevention and Control World Health Organization, 2011
  2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-128
  3. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by repre sentatives of nine societies and by invited experts). Atherosclerosis 2012; 223: 1-68
  4. Dinç G, Sözmen K, Gerçeklioğlu G, Arık H, Critchley J, Unal B. Decreasing trends in cardiovascular mortality in Turkey between 1988 and 2008. BMC Public Health 2013; 13: 896
  5. Ünal B, Sözmen K, Arık H, Gerçeklioğlu G, Altun DU, Şimşek H, et al. Explaining the decline in coronary heart disease mortality in Turkey between 1995 and 2008. BMC Public Health 2013; 13: 1135
  6. Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet 2011; 377: 578-86
  7. Ünal B, Sözmen K, Uçku R, Ergör G, Soysal A, Baydur H, et al. High prevalence of cardiovascular risk factors in a Western urban Turkish population: a community-based study. Anatol J Cardiol 2013; 13: 9-17
  8. Onat A. Lipids, lipoproteins and apolipoproteins among turks, and impact on coronary heart disease. Anatol J Cardiol 2004; 4: 236- 45
  9. Erem C, Hacıhasanoğlu A, Değer O, Koçak M, Topbaş M. Prevalence of dyslipidemia and associated risk factors among Turkish adults: Trabzon lipid study. Endocrine 2008; 34: 36-51
  10. Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol 2004; 24: e149-61
  11. Firmann M, Marques-Vidal P, Paccaud F, Mooser V, Rodondi N, Waeber G, et al. Prevalence, treatment and control of dyslipidaemia in Switzerland: still a long way to go. Eur J Cardiovasc Prev Rehabil 2010; 17: 682-7
  12. Rodriguez CJ, Ca